Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$883.20 USD
-7.48 (-0.84%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $881.43 -1.77 (-0.20%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
REGN 883.20 -7.48(-0.84%)
Will REGN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for REGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for REGN
EXEL vs. REGN: Which Stock Is the Better Value Option?
Intellia (NTLA) to Report Q1 Earnings: What's in the Cards?
REGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up
Regeneron (REGN) Reports Next Week: What You Should Expect
The Zacks Analyst Blog Highlights Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power
Other News for REGN
Interesting REGN Put And Call Options For June 7th
Regeneron price target raised by $50 at Oppenheimer, here's why
Analysts Are Bullish on Top Healthcare Stocks: Regeneron (REGN), Gilead Sciences (GILD)
Barclays Sticks to Their Buy Rating for Regeneron (REGN)
AbbVie reports positive results from Rinvoq versus Dupixent study